SCHEMBL971597

SCHEMBL971597

CC(C)c1ncc2c3c(sc2n1)CN(CC(=O)N1CCN(C2CCC2)CC1)CC3

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.39
KCNH2 Q12809 1/20 0.37
TMEM97 Q5BJF2 1/20 0.37
ALDH1A1 P00352 7/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HRH3 Q9Y5N1 4/20 0.34
KDM4E B2RXH2 5/20 0.33
HPGD P15428 4/20 0.33
MAPT P10636 2/20 0.33
HSD17B10 Q99714 2/20 0.33
G6PD P11413 1/20 0.33
CACNA1B Q00975 1/20 0.33
APBA1 Q02410 1/20 0.33
APOBEC3G Q9HC16 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
LMNA P02545 1/20 0.32
NPSR1 Q6W5P4 2/20 0.31
USP2 O75604 1/20 0.31
ALOX15 P16050 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL966767 0.89 PARP1 (0.40) PARP1TMEM97ALDH1A1L3MBTL1HRH3
SCHEMBL968565 0.88 PARP1 (0.39) PARP1ALDH1A1L3MBTL1HRH3KDM4E
SCHEMBL970417 0.88 PARP1 (0.40) PARP1TMEM97ALDH1A1L3MBTL1HRH3
SCHEMBL971385 0.87 PARP1 (0.39) PARP1ALDH1A1L3MBTL1HRH3KDM4E
SCHEMBL967692 0.87 PARP1 (0.39) PARP1ALDH1A1L3MBTL1HRH3KDM4E
SCHEMBL969349 0.87 PARP1 (0.40) PARP1KCNH2TMEM97ALDH1A1HRH3
SCHEMBL969371 0.87 PARP1 (0.40) PARP1KCNH2TMEM97ALDH1A1HRH3
SCHEMBL967160 0.87 PARP1 (0.40) PARP1TMEM97ALDH1A1L3MBTL1KDM4E
SCHEMBL969215 0.86 PARP1 (0.41) PARP1KCNH2TMEM97ALDH1A1L3MBTL1
SCHEMBL967717 0.85 PARP1 (0.39) PARP1TMEM97ALDH1A1HRH3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
WO-2009003003-A2 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 PARP1 2898/4885KCNH2 295/4885TMEM97 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.